Compare FuelCell Energy Inc (FCEL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? FuelCell Energy Inc trades at $17.51 (market cap $1.47B), while Vertex Pharmaceuticals Incorporated trades at $507.41 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 86.8× FuelCell Energy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FCEL | VRTX | |
|---|---|---|
Market Cap | $1.47B | $127.55B |
Volume | 12,559,948 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $36.01 | $557.96 |
52-Week Low | $6.00 | $407.37 |
Typical Hold Time | 48 Days | 120 Days |
Enterprise Value | $1.05B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $18.365, down 11.07% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $158.16M in 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading disclosures between June and September 2026.
FCEL faces significant financial challenges with persistent losses and negative cash flow from operations, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Investment opportunities exist if the company achieves profitability, but risks include ongoing litigation, execution risks in scaling operations, and competitive pressures in the clean energy sector.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
